Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial
Circulation · 2023
DOI: 10.1161/circulationaha.123.066485 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2023. Verfasst von Linda P T Joosten und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary Care & Nursing Science (L.P.T.J., S.v.D., B.T.G.K., F.H.R., G.-J.G.), University Medical Center Utrecht, Julius Center for Heal…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Frailty, Thromboembolism, Stroke. Die Arbeit wurde bisher 103-mal zitiert (Crossref). Gefördert von: ZonMw.
Abstract (Originalsprache)
Background
There is ambiguity whether frail patients with atrial fibrillation (AF) managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC).
Methods
We conducted a pragmatic, multicenter, open-label, randomized controlled superiority trial. Older AF patients living with frailty (age ≥75 years plus a Groningen Frailty Indicator (GFI) score ≥3) were randomized to switch from INR-guided VKA treatment to a NOAC or to continued VKA treatment. Patients with a glomerular filtration rate
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Primary Care & Nursing Science (L.P.T.J., S.v.D., B.T.G.K., F.H.R., G.-J.G.), University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht University, The Netherlands.
- Department of Data Science & Biostatistics (P.M.v.d.V.), University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht University, The Netherlands.
- Department of Thrombosis and Anticoagulation, Atalmedial Medical Diagnostic Centers, Amsterdam, The Netherlands (M.C.N.,).
- Department of Geriatrics, University Medical Center Utrecht, Utrecht University, The Netherlands (H.L.K.).
- Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands (M.E.W.H.).
- Department of Cardiology (M.E.W.H.), Radboud University Medical Center, Radboud University, Nijmegen, The Netherlands.
ORCID-Profile: Linda P T Joosten, Sander van Doorn, Peter M van de Ven, Melchior C Nierman, Huiberdina L Koek, Martin E W Hemels, Menno V Huisman, Marieke Kruip, Kit C Roes, Arno W Hoes, Frans H Rutten, Geert-Jan Geersing
Förderung
- ZonMw
Zitieren
APA
Joosten, L. P. T., van Doorn, S., van de Ven, P. M., Köhlen, B. T. G., Nierman, M. C., Koek, H. L., Hemels, M. E. W., Huisman, M. V., Kruip, M., Faber, L. M., Wiersma, N. M., Buding, W. F., Fijnheer, R., Adriaansen, H. J., Roes, K. C., Hoes, A. W., Rutten, F. H., & Geersing, G. J. (2023). Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. https://doi.org/10.1161/circulationaha.123.066485
Vancouver
Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2023. doi:10.1161/circulationaha.123.066485
BibTeX
@article{Joosten2023,
author = {Joosten, Linda P T and van Doorn, Sander and van de Ven, Peter M and Köhlen, Bart T G and Nierman, Melchior C and Koek, Huiberdina L and Hemels, Martin E W and Huisman, Menno V and Kruip, Marieke and Faber, Laura M and Wiersma, Nynke M and Buding, Wim F and Fijnheer, Rob and Adriaansen, Henk J and Roes, Kit C and Hoes, Arno W and Rutten, Frans H and Geersing, Geert-Jan},
title = {Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial},
journal = {Circulation},
year = {2023},
doi = {10.1161/circulationaha.123.066485}
}
EUVIMED